{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:39:01Z","timestamp":1787009941162,"version":"build-2736575974"},"reference-count":51,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:p>In this article we discuss the association of postural orthostatic tachycardia syndrome (POTS) with coronavirus-19 (COVID-19), ivabradine\u2019s unique mechanism of action, and its use in POTS patients. We highlight the pathophysiology and common etiologies of POTS, including preceding viral infections, vaccines, trauma, surgeries, and other stressors. COVID-19, a viral illness, has been associated with POTS through a variety of mechanisms that are not yet well understood. The initial management strategy for POTS is largely nonpharmacological, focusing on increasing venous return to the heart through physical therapy or other exercise activities.<\/jats:p>\n                  <jats:p>Ivabradine is a selective inhibitor of the funny sodium channels within the sinoatrial node. This unique mechanism of action allows for the reduction of heart rate without any effect on the heart\u2019s ionotropic activity. With an increase in the number of POTS cases, especially during the COVID pandemic, the importance of utilizing new medications and management strategies for POTS becomes imperative. Though ivabradine is currently only approved for the management of patients with coronary artery disease and heart failure by the Food and Drug Administration (FDA), it has also proven to be effective at reducing symptoms among patients with refractory POTS, and thus, should be considered for the management of patients who do not respond to initial treatment strategies.<\/jats:p>","DOI":"10.1097\/crd.0000000000000503","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T17:00:06Z","timestamp":1675357206000},"page":"279-284","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Postural Tachycardia Syndrome and COVID-19: Focus on Ivabradine Therapy"],"prefix":"10.1097","volume":"32","author":[{"given":"Keshav","family":"Dixit","sequence":"first","affiliation":[{"name":"Department of Medicine, ISMMS Mount Sinai Morningside-West, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Frishman","sequence":"additional","affiliation":[{"name":"Departments of Medicine and Cardiology, New York Medical College and Westchester Medical Center, Valhalla, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,12,5]]},"reference":[{"key":"R1-20250619","doi-asserted-by":"crossref","first-page":"e0028","DOI":"10.5041\/RMMJ.10213","article-title":"The effect of ivabradine on the heart rate and sympathovagal balance in postural tachycardia syndrome patients.","volume":"6","author":"Barzilai","year":"2015","journal-title":"Rambam Maimonides Med J"},{"key":"R2-20250619","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1146\/annurev-med-041818-011630","article-title":"Postural orthostatic tachycardia syndrome: mechanisms and new therapies.","volume":"71","author":"Mar","year":"2020","journal-title":"Annu Rev Med"},{"key":"R3-20250619","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1016\/j.hrthm.2015.03.029","article-title":"2015 Heart Rhythm Society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope.","volume":"12","author":"Sheldon","year":"2015","journal-title":"Heart Rhythm"},{"key":"R4-20250619","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/joim.12852","article-title":"Postural orthostatic tachycardia syndrome: clinical presentation, aetiology and management.","volume":"285","author":"Fedorowski","year":"2019","journal-title":"J Intern Med"},{"key":"R5-20250619","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJM200010053431404","article-title":"The neuropathic postural tachycardia syndrome.","volume":"343","author":"Jacob","year":"2000","journal-title":"N Engl J Med"},{"key":"R6-20250619","first-page":"255","article-title":"Increased plasma angiotensin II in postural tachycardia syndrome (POTS) is related to reduced blood flow and blood volume.","volume":"110","author":"Stewart","year":"2006","journal-title":"Clin Sci Lond Engl 1979"},{"key":"R7-20250619","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s11910-015-0583-8","article-title":"Postural tachycardia syndrome: beyond orthostatic intolerance.","volume":"15","author":"Garland","year":"2015","journal-title":"Curr Neurol Neurosci Rep"},{"key":"R8-20250619","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.autneu.2018.02.005","article-title":"Postural tachycardia syndrome - Diagnosis, physiology, and prognosis.","volume":"215","author":"Arnold","year":"2018","journal-title":"Auton Neurosci Basic Clin"},{"key":"R9-20250619","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.hrthm.2015.12.012","article-title":"The international POTS registry: evaluating the efficacy of an exercise training intervention in a community setting.","volume":"13","author":"George","year":"2016","journal-title":"Heart Rhythm"},{"key":"R10-20250619","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.autneu.2018.07.001","article-title":"Exercise and non-pharmacological treatment of POTS.","volume":"215","author":"Fu","year":"2018","journal-title":"Auton Neurosci Basic Clin"},{"key":"R11-20250619","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s10286-008-0487-7","article-title":"POTS versus deconditioning: the same or different?","volume":"18","author":"Joyner","year":"2008","journal-title":"Clin Auton Res Off J Clin Auton Res Soc"},{"key":"R12-20250619","first-page":"688","article-title":"Effect of selective alpha1 receptor agonist in the treatment of children with postural orthostatic tachycardia syndrome.","volume":"46","author":"Chen","year":"2008","journal-title":"Zhonghua Er Ke Za Zhi Chin J Pediatr"},{"key":"R13-20250619","first-page":"927","article-title":"Midodrine hydrochloride is effective in the treatment of children with postural orthostatic tachycardia syndrome.","volume":"75","author":"Chen","year":"2011","journal-title":"Circ J Off J Jpn Circ Soc"},{"key":"R14-20250619","doi-asserted-by":"crossref","first-page":"7836","DOI":"10.3390\/ijerph17217836","article-title":"Work ability assessment and its relationship with cardiovascular autonomic profile in postural orthostatic tachycardia syndrome.","volume":"17","author":"Barbic","year":"2020","journal-title":"Int J Environ Res Public Health"},{"key":"R15-20250619","first-page":"1","article-title":"A case report of postural tachycardia syndrome after COVID-19","author":"Miglis","year":"2020","journal-title":"Clin Auton Res"},{"key":"R16-20250619","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.hrthm.2020.12.007","article-title":"The possible association between COVID-19 and postural tachycardia syndrome.","volume":"18","author":"Goldstein","year":"2021","journal-title":"Heart Rhythm"},{"key":"R17-20250619","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.7861\/clinmed.2020-0896","article-title":"Autonomic dysfunction in \u201clong COVID\u201d: rationale, physiology and management strategies.","volume":"21","author":"Dani","year":"2021","journal-title":"Clin Med"},{"key":"R18-20250619","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1177\/0961203315587566","article-title":"Autoimmune markers and autoimmune disorders in patients with postural tachycardia syndrome (POTS).","volume":"24","author":"Blitshteyn","year":"2015","journal-title":"Lupus"},{"key":"R19-20250619","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.autneu.2018.04.005","article-title":"Autoimmunity in postural orthostatic tachycardia syndrome: Current understanding.","volume":"215","author":"Vernino","year":"2018","journal-title":"Auton Neurosci Basic Clin"},{"key":"R20-20250619","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/acn3.524","article-title":"Autoimmune postural orthostatic tachycardia syndrome.","volume":"5","author":"Watari","year":"2018","journal-title":"Ann Clin Transl Neurol"},{"key":"R21-20250619","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1177\/0961203316629558","article-title":"Postural Orthostatic Tachycardia Syndrome (POTS)--A novel member of the autoimmune family.","volume":"25","author":"Dahan","year":"2016","journal-title":"Lupus"},{"key":"R22-20250619","doi-asserted-by":"crossref","first-page":"624968","DOI":"10.3389\/fneur.2021.624968","article-title":"COVID-19 dysautonomia.","volume":"12","author":"Goodman","year":"2021","journal-title":"Front Neurol"},{"key":"R23-20250619","doi-asserted-by":"crossref","first-page":"100100","DOI":"10.1016\/j.jtauto.2021.100100","article-title":"Functional autoantibodies against G-protein coupled receptors in patients with persistent Long-COVID-19 symptoms.","volume":"4","author":"Wallukat","year":"2021","journal-title":"J Transl Autoimmun"},{"key":"R24-20250619","doi-asserted-by":"crossref","first-page":"H2098","DOI":"10.1152\/ajpheart.00409.2015","article-title":"Sympathetic activation is associated with increased IL-6, but not CRP in the absence of obesity: lessons from postural tachycardia syndrome and obesity.","volume":"309","author":"Okamoto","year":"2015","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"R25-20250619","doi-asserted-by":"crossref","DOI":"10.1111\/febs.15481","article-title":"Sympathetic activation: a potential link between comorbidities and COVID\u201019.","author":"Porzionato","year":"2020","journal-title":"FEBS J"},{"key":"R26-20250619","doi-asserted-by":"crossref","first-page":"341583","DOI":"10.1155\/2015\/341583","article-title":"Relevance of sympathetic nervous system activation in obesity and metabolic syndrome.","volume":"2015","author":"Thorp","year":"2015","journal-title":"J Diabetes Res"},{"key":"R27-20250619","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1161\/CIRCULATIONAHA.104.516948","article-title":"Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study.","volume":"112","author":"Dekker","year":"2005","journal-title":"Circulation"},{"key":"R28-20250619","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.19102\/icrm.2020.111102","article-title":"New-onset postural orthostatic tachycardia syndrome following coronavirus disease 2019 infection.","volume":"11","author":"Kanjwal","year":"2020","journal-title":"J Innov Card Rhythm Manag"},{"key":"R29-20250619","doi-asserted-by":"crossref","first-page":"e1060","DOI":"10.1212\/WNL.0000000000009937","article-title":"Neurologic manifestations in hospitalized patients with COVID-19.","volume":"95","author":"Romero-S\u00e1nchez","year":"2020","journal-title":"Neurology"},{"key":"R30-20250619","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s12026-021-09185-5","article-title":"Postural orthostatic tachycardia syndrome (POTS) and other autonomic disorders after COVID-19 infection: a case series of 20 patients.","volume":"69","author":"Blitshteyn","year":"2021","journal-title":"Immunol Res"},{"key":"R31-20250619","first-page":"e14837","article-title":"A case of postural orthostatic tachycardia syndrome secondary to the messenger RNA COVID-19 vaccine.","volume":"13","author":"Reddy","year":"2021","journal-title":"Cureus"},{"key":"R32-20250619","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/ene.12272","article-title":"Postural tachycardia syndrome following human papillomavirus vaccination.","volume":"21","author":"Blitshteyn","year":"2014","journal-title":"Eur J Neurol"},{"key":"R33-20250619","first-page":"7809231","article-title":"Clinical and laboratory improvement in hyperadrenergic postural orthostatic tachycardia syndrome (POTS) after COVID-19 infection.","volume":"2021","author":"Ocher","year":"2021","journal-title":"Case Rep Cardiol"},{"key":"R35-20250619","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1016\/j.jacc.2017.08.038","article-title":"The Clinical Use of Ivabradine.","volume":"70","author":"Koruth","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"R36-20250619","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.pharmthera.2005.01.005","article-title":"Physiology and pharmacology of the cardiac pacemaker (\u201cfunny\u201d) current.","volume":"107","author":"Baruscotti","year":"2005","journal-title":"Pharmacol Ther"},{"key":"R37-20250619","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(08)61171-X","article-title":"Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial.","volume":"372","author":"Fox","year":"2008","journal-title":"Lancet Lond Engl"},{"key":"R38-20250619","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1093\/eurheartj\/ehp358","article-title":"Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial.","volume":"30","author":"Fox","year":"2009","journal-title":"Eur Heart J"},{"key":"R39-20250619","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa1406430","article-title":"Ivabradine in stable coronary artery disease without clinical heart failure.","volume":"371","author":"Fox","year":"2014","journal-title":"N Engl J Med"},{"key":"R40-20250619","doi-asserted-by":"crossref","first-page":"300","DOI":"10.15420\/aer.2019.30.2","article-title":"Ivabradine and AF: coincidence, correlation or a new treatment?","volume":"8","author":"Abdelnabi","year":"2020","journal-title":"Arrhythmia Electrophysiol Rev"},{"key":"R41-20250619","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/ejhf.258","article-title":"Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy.","volume":"17","author":"B\u00f6hm","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"R42-20250619","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1016\/j.jacc.2021.03.338","article-title":"Ivabradine in POTS: increase in central pressure rather than down-regulation of sympathetic nervous system.","volume":"77","author":"Messerli","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"R43-20250619","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1540-8159.2009.02186.x","article-title":"Treatment of inappropriate sinus tachycardia with ivabradine in a patient with postural orthostatic tachycardia syndrome and a dual chamber pacemaker.","volume":"32","author":"Khan","year":"2009","journal-title":"Pacing Clin Electrophysiol PACE"},{"key":"R44-20250619","first-page":"273","article-title":"Use of ivabradine in postural orthostatic tachycardia syndrome.","volume":"3","author":"Jamil-Copley","year":"2010","journal-title":"J Atr Fibrillation"},{"key":"R45-20250619","first-page":"285","article-title":"Successful use of ivabradine in a case of exaggerated autonomic dysfunction.","volume":"38","author":"Aliyev","year":"2010","journal-title":"Arch Turk Soc Cardiol"},{"key":"R46-20250619","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/europace\/euq390","article-title":"Single centre experience of ivabradine in postural orthostatic tachycardia syndrome.","volume":"13","author":"McDonald","year":"2011","journal-title":"Europace"},{"key":"R47-20250619","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/pace.13182","article-title":"Ivabradine in the treatment of postural tachycardia syndrome (POTS), a single center experience.","volume":"40","author":"Ruzieh","year":"2017","journal-title":"Pacing Clin Electrophysiol PACE"},{"key":"R48-20250619","doi-asserted-by":"crossref","first-page":"e227789","DOI":"10.1136\/bcr-2018-227789","article-title":"Is ivabradine a wonder drug for atypical POTS?","volume":"12","author":"Cheema","year":"2019","journal-title":"BMJ Case Rep"},{"key":"R49-20250619","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s40256-017-0248-x","article-title":"Ivabradine in postural orthostatic tachycardia syndrome: preliminary experience in children.","volume":"18","author":"Delle Donne","year":"2018","journal-title":"Am J Cardiovasc Drugs Drugs Devices Interv"},{"key":"R50-20250619","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1093\/europace\/eut226","article-title":"Ivabradine in treatment of sinus tachycardia mediated vasovagal syncope.","volume":"16","author":"Sutton","year":"2014","journal-title":"Eurpace"},{"key":"R51-20250619","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jacc.2020.12.029","article-title":"Randomized trial of ivabradine in patients with hyperadrenergic postural orthostatic tachycardia syndrome.","volume":"77","author":"Taub","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"R52-20250619","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s10286-022-00867-0","article-title":"A case series of cutaneous phosphorylated \u03b1-synuclein in long-COVID POTS.","volume":"32","author":"Miglis","year":"2022","journal-title":"Clin Auton Res"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000503","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T12:03:15Z","timestamp":1750334595000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,5]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000503","relation":{},"ISSN":["1061-5377"],"issn-type":[{"value":"1061-5377","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12,5]]}}}